This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Farb, A. Articles by Virmani, R. Search for Related Content PubMed PubMed Citation Articles by Farb, A. Articles by Virmani, R.

(Circulation Research. 1997;80:542-550.)
© 1997 American Heart Association, Inc.

Articles

Vascular Smooth Muscle Cell Cytotoxicity and Sustained Inhibition of Neointimal Formation by Fibroblast Growth Factor 2–Saporin Fusion Protein

Andrew Farb, Sue J. Lee, Duk H. Min, Zahra Parandoosh, Jennifer Cook, John McDonald, Glenn F. Pierce, , Renu Virmani

From the Department of Cardiovascular Pathology (A.F., S.J.L., D.H.M., R.V.), Armed Forces Institute of Pathology, Washington, DC, and Prizm Pharmaceuticals (Z.P., J.C., J.M., G.F.P.), San Diego, Calif.

Abstract Basic fibroblast growth factor (FGF2) is an important mediator of smooth muscle cell (SMC) proliferation following arterial injury that results in neointimal growth. The present study was designed to explore the effects of recombinant FGF2 linked to the ribosome-inactivating protein saporin-6 (rFGF2-SAP) on vascular SMC cytotoxicity and neointimal formation following arterial injury. Cultured rat aortic SMCs were exposed to various concentrations of rFGF2-SAP, FGF2, and saporin-6 (SAP). Incubation with rFGF2-SAP resulted in a decreased number of SMCs beginning at a concentration of 10^-9 mol/L. Significant cytotoxicity was observed with as little as a 30-minute exposure of SMCs to rFGF2-SAP. To evaluate the ability of rFGF2-SAP in an in vivo model to reduce neointimal formation, Sprague-Dawley rats underwent carotid artery balloon denudation and received an intravenous bolus of vehicle or 5, 10, 15, or 20 µg/kg rFGF2-SAP on 0, 3, 6, and 9 days after injury. Rats were euthanized at 14 days, and carotid arteries were analyzed by computerized morphometry. The threshold dose for a significant reduction in neointimal area by rFGF2-SAP was 15 µg/kg (47% reduction in neointima). When dosing was extended to include days 16, 19, and 22, the neointima was reduced 33% at 28 days (P=.048). rFGF2-SAP reduced neointima without associated medial thinning or arterial wall dilatation. To determine if rFGF2-SAP directly targets SMCs in vivo, rats underwent carotid injury and received either 15 µg/kg rFGF2-SAP or vehicle on day 0 and at 72 hours, with euthanasia at 78 hours after balloon denudation. Medial SMC number was reduced 46% in the rFGF2-SAP group. Tissue sections from arteries 3 days after balloon injury demonstrated rFGF2-SAP binding to medial SMCs and adventitial cells. Staining for fibroblast growth factor receptor 1 revealed a high level of expression in ballooned arteries 3 and 14 days after injury. Taken together, these results provide a molecular and cellular basis for the observed specificity. Prolonged delivery of rFGF2-SAP can affect the natural history of arterial repair after injury.

Key Words: restenosis • saporin • fibroblast growth factor • neointima

This article has been cited by other articles:

				G. Li, S. Oparil, S. S. Kelpke, Y.-F. Chen, and J. A. Thompson Fibroblast Growth Factor Receptor-1 Signaling Induces Osteopontin Expression and Vascular Smooth Muscle Cell-Dependent Adventitial Fibroblast Migration In Vitro Circulation, August 13, 2002; 106(7): 854 - 859. [Abstract] [Full Text] [PDF]

				P.-L. Tazzari, L. Polito, A. Bolognesi, M.-P. Pistillo, P. Capanni, G. L. Palmisano, R. M. Lemoli, A. Curti, L. Biancone, G. Camussi, et al. Immunotoxins Containing Recombinant Anti-CTLA-4 Single-Chain Fragment Variable Antibodies and Saporin: In Vitro Results and In Vivo Effects in an Acute Rejection Model J. Immunol., October 15, 2001; 167(8): 4222 - 4229. [Abstract] [Full Text] [PDF]